OUTLOOK

A visual guide to migraine headaches

The pain, the pressure, the way it ruins your mood — everyone has experienced a headache at one time or another. But whereas most are transient and easily managed, migraines are stubborn and debilitating.
Neil Savage is a freelance science writer in Lowell, Massachusetts.

Search for this author in:

Blueprint of a migraine

A migraine attack comprises several phases, of which the headache is just one: other symptoms, such as fatigue and muscle stiffness, can precede the headache by several days and linger after it has passed. Some people also experience neurological disturbances known as aura. The mechanisms behind pain and aura are not certain, but theories abound.

A painful pathway

The headache phase can last between 4 and 72 hours. It is characterized by pulsing or throbbing pain on one or both sides of the head, nausea and vomiting, and sensitivity to light, sound, smell and touch. The leading theory of migraine is that headache is the result of activation of the trigeminovascular system, the network of nerves linked to blood vessels in the head.

Source: D. W. Dodick Headache 58 (Suppl. 1), 4–16 (2018); Graphic: Alisdair Macdonald and Denis Mallet

Strange sensations

Symptoms include seeing lights or shapes, vision loss and prickling sensations in an arm or leg. They develop over 15–20 minutes and last less than an hour.

It is widely thought that auras are caused by a slow-moving wave of depolarization that passes through the brain, known as cortical spreading depression (CSD).

Pharmaceutical options

Drugs are not the only choice for treating migraine, but there are numerous options available, including over-the-counter non-steroidal anti-inflammatory drugs, opioids and monoclonal antibodies. They work by various mechanisms, not all of which are completely understood, to interrupt the pain.

Triptans

Tryptamine-based drugs were introduced in the 1990s. They mimic the activity of the neurotransmitter serotonin (5-HT) and are effective in the early stages of an attack. At 5-HT1B receptors, they reduce pain by causing cranial blood vessels to constrict. At 5-HT1D receptors, they block the release of neuropeptides that trigger inflammation.

Graphic: Alisdair Macdonald and Denis Mallet

Monoclonal antibodies

Monoclonal antibodies against CGRP, first approved in 2019, are given by injection to prevent migraine attacks. The antibodies bind to either CGRP or its receptor to stop the peptide from dilating blood vessels and increasing inflammation in the meninges. They also block the transmission of pain along the trigeminal pathway.

Graphic: Alisdair Macdonald and Denis Mallet

Botox

Onabotulinumtoxin A, or Botox, is a neurotoxin that was approved for use in chronic migraine in the United States in 2010. It is given by injection and can prevent attacks for up to 90 days. Botox interferes with the neurotransmitter acetylcholine (ACh) by breaking a protein required for its release at a synapse. This prevents ACh from activating pain-receptor fibres in the brain.

Graphic: Alisdair Macdonald and Denis Mallet

Migraine and its cousins

Migraine is a major category of headache, but it is not the only type. Tension headaches are more common, yet generally less painful, whereas cluster headaches are excruciatingly painful but fortunately rare.

Source: GBD 2016 Headache Collaborators. Lancet Neurol. 17, 954–976 (2018); Graphic: Alisdair Macdonald and Denis Mallet

Source: GBD 2016 Headache Collaborators. Lancet Neurol. 17, 954–976 (2018); Graphic: Alisdair Macdonald and Denis Mallet

Source: GBD 2016 Headache Collaborators. Lancet Neurol. 17, 954–976 (2018); Graphic: Alisdair Macdonald and Denis Mallet

Nature 586, S2-S3 (2020)

This article is part of Nature Outlook: Headache, an editorially independent supplement produced with the financial support of third parties. About this content.

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.